Acinic cell carcinoma diagnostic study of choice: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
(Created page with "__NOTOC__ {{Acinic cell carrcinoma}} {{CMG}}; {{AE}} {{RG}} == Overview == == Diagnostic Study of Choice == === Study of choice === [Name of the investigation] is the gold s...")
 
No edit summary
 
(3 intermediate revisions by the same user not shown)
Line 1: Line 1:
__NOTOC__
__NOTOC__
{{Acinic cell carrcinoma}}
 
{{Acinic cell carcinoma}}
 
{{CMG}}; {{AE}} {{RG}}
{{CMG}}; {{AE}} {{RG}}
== Overview ==
== Overview ==
The presence of tumor in parotid gland is first detected by its symptoms and then its consistency is further analysed by CT-scan. Recurrent abnormality of [[Cytogenetics|cytogenetic]] t(12;15) ETV6-NRTK3  is the gold standard test for the diagnosis of acinic cell carcinoma.


== Diagnostic Study of Choice ==
== Diagnostic Study of Choice ==


=== Study of choice ===
=== Study of choice ===
[Name of the investigation] is the gold standard test for the diagnosis of [disease name].
OR
The following result of [gold standard test] is confirmatory of [disease name]:
* [Result 1]
* [Result 2]
OR
[Name of the investigation] must be performed when:
* The patient presents with [symptom/sign 1], [symptom/sign 2], and [symptom/sign 3].
* A [name of test] is positive for [sign 1], [sign 2], and [sign 3] in the patient.
OR
[Name of the investigation] is the gold standard test for the diagnosis of [disease name].
OR
The diagnostic study of choice for [disease name] is [name of the investigation].
OR
There is no single diagnostic study of choice for the diagnosis of [disease name].
OR
There is no single diagnostic study of choice for the diagnosis of [disease name], but [disease name] can be diagnosed based on [name of the investigation 1] and [name of the investigation 2].
OR
[Disease name] is primarily diagnosed based on the clinical presentation.
OR
Investigations:
* Among the patients who present with clinical signs of [disease name], the [investigation name] is the most specific test for the diagnosis.
* Among the patients who present with clinical signs of [disease name], the [investigation name] is the most sensitive test for diagnosis.
* Among the patients who present with clinical signs of [disease name], the [investigation name] is the most efficient test for diagnosis.
==== The comparison of various diagnostic studies for [disease name] ====
{|
|- style="background: #4479BA; color: #FFFFFF; text-align: center;"
! style="background: #4479BA; color: #FFFFFF; text-align: center;" | Test
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Sensitivity
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Specificity
|-
! style="background: #696969; color: #FFFFFF; text-align: center;" |Test 1
| style="background: #DCDCDC; padding: 5px; text-align: center;" |...%
| style="background: #DCDCDC; padding: 5px; text-align: center;" |...%
|-
! style="background: #696969; color: #FFFFFF; text-align: center;" |Test 2
| style="background: #DCDCDC; padding: 5px; text-align: center;" |...%
| style="background: #DCDCDC; padding: 5px; text-align: center;" |...%
|}
<small> [Name of test with higher sensitivity and specificity] is the preferred investigation based on the sensitivity and specificity</small>
===== Diagnostic results =====
The following finding(s) on performing [investigation name] is(are) confirmatory for [disease name]:
* [Finding 1]
* [Finding 2]
===== Sequence of Diagnostic Studies =====
The [name of investigation] must be performed when:
* The patient presented with symptoms/signs 1, 2, and 3 as the first step of diagnosis.
* A positive [test] is detected in the patient, to confirm the diagnosis.
OR
The various investigations must be performed in the following order:
* [Initial investigation]
* [2nd investigation]
=== Name of Diagnostic Criteria ===
'''It is recommended that you include the criteria in a table. Make sure you always cite the source of the content and whether the table has been adapted from another source.'''
[Disease name] is primarily diagnosed based on clinical presentation. There are no established criteria for the diagnosis of [disease name].
OR
There is no single diagnostic study of choice for [disease name], though [disease name] may be diagnosed based on [name of criteria] established by [...].
OR
The diagnosis of [disease name] is made when at least [number] of the following [number] diagnostic criteria are met: [criterion 1], [criterion 2], [criterion 3], and [criterion 4].
OR
The diagnosis of [disease name] is based on the [criteria name] criteria, which includes [criterion 1], [criterion 2], and [criterion 3].
OR
[Disease name] may be diagnosed at any time if one or more of the following criteria are met:
* Criteria 1
* Criteria 2
* Criteria 3
OR
'''IF there are clear, established diagnostic criteria'''
The diagnosis of [disease name] is made when at least [number] of the following [number] diagnostic criteria are met: [criterion 1], [criterion 2], [criterion 3], and [criterion 4].
OR
The diagnosis of [disease name] is based on the [criteria name] criteria, which include [criterion 1], [criterion 2], and [criterion 3].
OR
The diagnosis of [disease name] is based on the [definition name] definition, which includes [criterion 1], [criterion 2], and [criterion 3].
OR


'''IF there are no established diagnostic criteria'''
* The presence of tumor in [[parotid gland]] is first detected by its symptoms and then its consistency is further analysed by [[CT-scan]]. <ref name="pmid22058591">{{cite journal| author=Bussu F, Parrilla C, Rizzo D, Almadori G, Paludetti G, Galli J| title=Clinical approach and treatment of benign and malignant parotid masses, personal experience. | journal=Acta Otorhinolaryngol Ital | year= 2011 | volume= 31 | issue= 3 | pages= 135-43 | pmid=22058591 | doi= | pmc=3185824 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22058591  }}</ref>
* Recurrent abnormality of [[Cytogenetics|cytogenetic]] t(12;15) ETV6-NRTK3  is the gold standard test for the diagnosis of acinic cell carcinoma.<ref name="RipamontiColombo2013">{{cite journal|last1=Ripamonti|first1=Carla B|last2=Colombo|first2=Mara|last3=Mondini|first3=Patrizia|last4=Siranoush|first4=Manoukian|last5=Peissel|first5=Bernard|last6=Bernard|first6=Loris|last7=Radice|first7=Paolo|last8=Carcangiu|first8=Maria Luisa|title=First description of an acinic cell carcinoma of the breast in a BRCA1 mutation carrier: a case report|journal=BMC Cancer|volume=13|issue=1|year=2013|issn=1471-2407|doi=10.1186/1471-2407-13-46}}</ref>


There are no established criteria for the diagnosis of [disease name].
<br />


==References==
==References==

Latest revision as of 15:03, 4 November 2019


Acinic cell carcinoma Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Acinic cell carcinoma from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Surgery

Medical Therapy

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case studies

Case #1

Acinic cell carcinoma diagnostic study of choice On the Web

Most recent articles

cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Acinic cell carcinoma diagnostic study of choice

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Acinic cell carcinoma diagnostic study of choice

CDC on Acinic cell carcinoma diagnostic study of choice

Acinic cell carcinoma diagnostic study of choice in the news

Blogs on Acinic cell carcinoma diagnostic study of choice

Directions to Hospitals Treating Acinic cell carcinoma

Risk calculators and risk factors for Acinic cell carcinoma diagnostic study of choice

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ramyar Ghandriz MD[2]

Overview

The presence of tumor in parotid gland is first detected by its symptoms and then its consistency is further analysed by CT-scan. Recurrent abnormality of cytogenetic t(12;15) ETV6-NRTK3 is the gold standard test for the diagnosis of acinic cell carcinoma.

Diagnostic Study of Choice

Study of choice

  • The presence of tumor in parotid gland is first detected by its symptoms and then its consistency is further analysed by CT-scan. [1]
  • Recurrent abnormality of cytogenetic t(12;15) ETV6-NRTK3 is the gold standard test for the diagnosis of acinic cell carcinoma.[2]


References

  1. ↑ Bussu F, Parrilla C, Rizzo D, Almadori G, Paludetti G, Galli J (2011). "Clinical approach and treatment of benign and malignant parotid masses, personal experience". Acta Otorhinolaryngol Ital. 31 (3): 135–43. PMC 3185824. PMID 22058591.
  2. ↑ Ripamonti, Carla B; Colombo, Mara; Mondini, Patrizia; Siranoush, Manoukian; Peissel, Bernard; Bernard, Loris; Radice, Paolo; Carcangiu, Maria Luisa (2013). "First description of an acinic cell carcinoma of the breast in a BRCA1 mutation carrier: a case report". BMC Cancer. 13 (1). doi:10.1186/1471-2407-13-46. ISSN 1471-2407.

Template:WH Template:WS

Retrieved from "https://www.wikidoc.org/index.php?title=Acinic_cell_carcinoma_diagnostic_study_of_choice&oldid=1587898"